1201 related articles for article (PubMed ID: 27185471)
1. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
2. Human natural killer cells: origin, receptors, function, and clinical applications.
Moretta L; Montaldo E; Vacca P; Del Zotto G; Moretta F; Merli P; Locatelli F; Mingari MC
Int Arch Allergy Immunol; 2014; 164(4):253-64. PubMed ID: 25323661
[TBL] [Abstract][Full Text] [Related]
3. Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation.
Marcenaro E; Carlomagno S; Pesce S; Della Chiesa M; Moretta A; Sivori S
J Leukoc Biol; 2011 Oct; 90(4):661-7. PubMed ID: 21791599
[TBL] [Abstract][Full Text] [Related]
4. Human NK receptors: from the molecules to the therapy of high risk leukemias.
Moretta L; Locatelli F; Pende D; Sivori S; Falco M; Bottino C; Mingari MC; Moretta A
FEBS Lett; 2011 Jun; 585(11):1563-7. PubMed ID: 21554879
[TBL] [Abstract][Full Text] [Related]
5. Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias.
Moretta A; Pende D; Locatelli F; Moretta L
Clin Exp Immunol; 2009 Sep; 157(3):325-31. PubMed ID: 19664139
[TBL] [Abstract][Full Text] [Related]
6. Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation.
Locatelli F; Bauquet A; Palumbo G; Moretta F; Bertaina A
Immunol Lett; 2013; 155(1-2):21-3. PubMed ID: 24091162
[TBL] [Abstract][Full Text] [Related]
7. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.
Sivori S; Vacca P; Del Zotto G; Munari E; Mingari MC; Moretta L
Cell Mol Immunol; 2019 May; 16(5):430-441. PubMed ID: 30778167
[TBL] [Abstract][Full Text] [Related]
8. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.
Norell H; Moretta A; Silva-Santos B; Moretta L
J Leukoc Biol; 2013 Dec; 94(6):1123-39. PubMed ID: 24108703
[TBL] [Abstract][Full Text] [Related]
9. Markers and function of human NK cells in normal and pathological conditions.
Del Zotto G; Marcenaro E; Vacca P; Sivori S; Pende D; Della Chiesa M; Moretta F; Ingegnere T; Mingari MC; Moretta A; Moretta L
Cytometry B Clin Cytom; 2017 Mar; 92(2):100-114. PubMed ID: 28054442
[TBL] [Abstract][Full Text] [Related]
10. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias.
Moretta A; Locatelli F; Moretta L
Immunol Rev; 2008 Aug; 224():58-69. PubMed ID: 18759920
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cells in the treatment of high-risk acute leukaemia.
Locatelli F; Moretta F; Brescia L; Merli P
Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
[TBL] [Abstract][Full Text] [Related]
12. Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation.
Ruggeri L; Capanni M; Mancusi A; Urbani E; Perruccio K; Burchielli E; Tosti A; Topini F; Aversa F; Martelli MF; Velardi A
Blood Cells Mol Dis; 2004; 33(3):216-21. PubMed ID: 15528134
[TBL] [Abstract][Full Text] [Related]
13. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
[TBL] [Abstract][Full Text] [Related]
15. Exploiting Human NK Cells in Tumor Therapy.
Vacca P; Pietra G; Tumino N; Munari E; Mingari MC; Moretta L
Front Immunol; 2019; 10():3013. PubMed ID: 32010130
[TBL] [Abstract][Full Text] [Related]
16. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C
Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361
[TBL] [Abstract][Full Text] [Related]
17. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference.
Locatelli F; Pende D; Maccario R; Mingari MC; Moretta A; Moretta L
Clin Immunol; 2009 Nov; 133(2):171-8. PubMed ID: 19481979
[TBL] [Abstract][Full Text] [Related]
18. Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation.
Rathmann S; Glatzel S; Schönberg K; Uhrberg M; Follo M; Schulz-Huotari C; Kaymer M; Veelken H; Finke J; Fisch P
Biol Blood Marrow Transplant; 2010 Apr; 16(4):469-81. PubMed ID: 20044012
[TBL] [Abstract][Full Text] [Related]
19. Bridging innate NK cell functions with adaptive immunity.
Marcenaro E; Carlomagno S; Pesce S; Moretta A; Sivori S
Adv Exp Med Biol; 2011; 780():45-55. PubMed ID: 21842364
[TBL] [Abstract][Full Text] [Related]
20. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation.
Moretta L; Locatelli F; Pende D; Marcenaro E; Mingari MC; Moretta A
Blood; 2011 Jan; 117(3):764-71. PubMed ID: 20889923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
